A Single-Center, Open-Label, Parallel Study to Investigate the Effects of Multiple Doses of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of RO4602522 in Healthy Male Subjects.

Completed

• Conditions: Alzheimer's disease; dementia; 10029305

• Registration Number: NL-OMON36948
• Lead Sponsor: F. Hoffmann-La Roche Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 34

Inclusion Criteria

healthy male subjects
18-45 yrs, inclusive
BMI: 18.0-30.0 kg/m2, inclusive
non-smoking

Exclusion Criteria

Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pharmacokinetics:<br /><br>Bloodsamples for the analysis of RO4602522 and metabolitesy will be collected<br /><br>during the clinic period.<br /><br><br /><br>Urine for the analysis of RO4602522 will be collected during the clinic period<br /><br>at he clinic until 48 hours after dosing.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>NA</p><br>